Related Experiment Videos
Prevalence and ramifications of chronic constipation
1Mayo Clinic, Scottsdale, Arizona 85259, USA.
Managed Care Interface
|September 1, 2005
Summary
Constipation affects many North Americans, but its exact prevalence is unknown due to varying definitions. New treatments are emerging for chronic idiopathic constipation, offering hope beyond traditional, often ineffective, therapies.
Area of Science:
- Gastroenterology
- Internal Medicine
- Pharmacology
Background:
- Constipation is a prevalent gastrointestinal condition impacting 2%–27% of North Americans.
- Lack of consensus definitions complicates accurate prevalence assessment.
- Constipation incurs significant socioeconomic costs and affects daily life, yet only one-third seek medical care.
Purpose of the Study:
- To address the limitations of traditional constipation treatments.
- To introduce a novel therapeutic agent for chronic idiopathic constipation (CIC).
- To leverage improved understanding of CIC pathophysiology for treatment development.
Main Methods:
- Review of existing literature on constipation prevalence and treatment efficacy.
- Analysis of the pathophysiology of chronic idiopathic constipation.
- Evaluation of a newly developed and approved pharmacological agent for CIC.
Main Results:
- Traditional interventions like fiber and laxatives lack high-quality efficacy evidence and often lead to patient dissatisfaction.
- A new agent has been developed and approved for treating chronic idiopathic constipation.
- Advances in understanding constipation pathophysiology have driven therapeutic innovation.
Conclusions:
- Existing treatments for constipation are often unsatisfactory.
- A new pharmacological option is now available for patients with chronic idiopathic constipation.
- Further research and improved diagnostic criteria are needed to better manage constipation.